enGene Therapeutics Inc. Net Income
enGene Therapeutics Inc. (ENGN) reported Net Income of -$32.50 million for the 3-month period ending 2026-07-31, per its 10-Q filed 2026-09-08.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-09-08
- enGene Therapeutics Inc. net income (loss) attributable to parent for the quarter ending 2026-07-31 was -$32.50M.
- enGene Therapeutics Inc. net income (loss) attributable to parent for the quarter ending 2026-04-30 was -$30.23M.
- enGene Therapeutics Inc. net income (loss) attributable to parent for the quarter ending 2026-01-31 was -$29.75M.
- enGene Therapeutics Inc. net income (loss) attributable to parent for the quarter ending 2025-10-31 was -$37.88M.
- enGene Therapeutics Inc. net income (loss) attributable to parent for fiscal 2025 was -$117.30M.
- enGene Therapeutics Inc. net income (loss) attributable to parent for fiscal 2024 was -$55.14M.
- enGene Therapeutics Inc. net income (loss) attributable to parent for fiscal 2023 was -$99.92M.
- enGene Therapeutics Inc. net income (loss) attributable to parent for fiscal 2022 was -$24.46M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-07-31 | -$32.50M 10-Q · filed 2026-09-08 | -$62.73M derived: sum of 2 quarters · filed 2026-09-08 | -$92.48M 10-Q · filed 2026-09-08 | -$130.36M derived: sum of 4 quarters · filed 2026-09-08 |
| 2026-04-30 | -$30.23M 10-Q · filed 2026-09-08 | -$59.98M 10-Q · filed 2026-06-15 | -$97.86M derived: sum of 3 quarters · filed 2026-09-08 | -$126.85M derived: sum of 4 quarters · filed 2026-09-08 |
| 2026-01-31 | -$29.75M 10-Q · filed 2026-09-08 | -$67.63M derived: sum of 2 quarters · filed 2026-09-08 | -$96.62M derived: sum of 3 quarters · filed 2026-09-08 | -$122.44M derived: sum of 4 quarters · filed 2026-09-08 |
| 2025-10-31 | -$37.88M derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-22 | -$66.87M derived: sum of 2 quarters · filed 2026-09-08 | -$92.69M derived: sum of 3 quarters · filed 2026-09-08 | -$117.30M 10-K · filed 2025-12-22 |
| 2025-07-31 | -$28.99M 10-Q · filed 2026-09-08 | -$54.81M derived: sum of 2 quarters · filed 2026-09-08 | -$79.42M 10-Q · filed 2026-09-08 | -$94.72M derived: sum of 4 quarters · filed 2026-09-08 |
| 2025-04-30 | -$25.82M 10-Q · filed 2026-09-08 | -$50.43M 10-Q · filed 2026-06-15 | -$65.73M derived: sum of 3 quarters · filed 2026-09-08 | -$79.88M derived: sum of 4 quarters · filed 2026-09-08 |
| 2025-01-31 | -$24.62M 10-Q · filed 2026-09-08 | -$39.91M derived: sum of 2 quarters · filed 2026-09-08 | -$54.06M derived: sum of 3 quarters · filed 2026-09-08 | -$69.05M derived: sum of 4 quarters · filed 2026-09-08 |
| 2024-10-31 | -$15.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-22 | -$29.45M derived: sum of 2 quarters · filed 2025-12-22 | -$44.43M derived: sum of 3 quarters · filed 2025-12-22 | -$55.14M 10-K · filed 2025-12-22 |
| 2024-07-31 | -$14.15M 10-Q · filed 2025-09-11 | -$29.13M derived: sum of 2 quarters · filed 2025-09-11 | -$39.84M 10-Q · filed 2025-09-11 | -$122.34M derived: sum of 4 quarters · filed 2025-09-11 |
| 2024-04-30 | -$14.98M 10-Q · filed 2025-09-11 | -$25.70M 10-Q · filed 2025-06-12 | -$108.19M derived: sum of 3 quarters · filed 2025-09-11 | -$112.91M derived: sum of 4 quarters · filed 2025-09-11 |
| 2024-01-31 | -$10.71M 10-Q · filed 2025-09-11 | -$93.21M derived: sum of 2 quarters · filed 2025-09-11 | -$97.93M derived: sum of 3 quarters · filed 2025-09-11 | -$103.21M derived: sum of 4 quarters · filed 2025-09-11 |
| 2023-10-31 | -$82.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-19 | -$87.22M derived: sum of 2 quarters · filed 2024-12-19 | -$92.50M derived: sum of 3 quarters · filed 2024-12-19 | -$99.92M 10-K · filed 2024-12-19 |
| 2023-07-31 | -$4.72M 10-Q · filed 2024-09-10 | -$10.00M derived: sum of 2 quarters · filed 2024-09-10 | -$17.42M 10-Q · filed 2024-09-10 | |
| 2023-04-30 | -$5.28M 10-Q · filed 2024-09-10 | -$12.70M 10-Q · filed 2024-06-14 | ||
| 2023-01-31 | -$7.42M 10-Q · filed 2024-09-10 | |||
| 2022-10-31 | -$24.46M 10-K · filed 2024-01-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |